An Open Label, Non-Randomized Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

Protocol No
IIT-BRADLEY-ENDOBARR
Principal Investigator
William Bradley
Phase
II
Summary
This is a phase II, Multi site trial evaluating the efficacy of combination therapy of Bevacizumab (anti-Angiogenesis drug), Atezolizumab (anti PD-L1 drug) and Rucaparib ( PARP inhibitor) with recurrent endometrial cancer
Description
To see combining three drugs, Bevacizumab, Atezolizumab and Rucaparib works well for previously treated recurrent Endometrial Cancer.
Participating Institutions
St. Luke's University Health Network
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: